Medicine details

ImagePilo DROP 2%
NamePilo DROP 2%
DosageEye Drops
Generic NamePilocarpine Hydrochloride
Classes Central Nervous System Agent
Dermatological/Topical Agent
Ophthalmic Preparation
Glaucoma Agent
Cholinergic Agent
Diseases Dry Mouth
Glaucoma
CompanyReman Drug Laboratories Ltd.

Drug Package Details

Strength2%
Storage Condition
Origin CountryBangladesh
Commercial Pack1
Price per pack200.00
Cost per pack176.00
Package unit10 ml drops
Price per unit200.00
Cost per unit176.00
Discount0
Coupon
Remarks

Pilocarpine Hydrochloride

Pilocarpine hydrochloride is a cholinergic parasympathomimetic agent that works by directly stimulating muscarinic receptors and smooth muscle in the iris and secretory glands. Pilocarpine contracts the ciliary muscle, increasing scleral spur tension and opening trabecular meshwork spaces to allow aqueous humor outflow. Outflow resistance is reduced, resulting in lower intraocular pressure (IOP). Pilocarpine causes miosis by contracting the iris sphincter muscle. Miosis alleviates appositional angle narrowing and closure, lowering IOP in angle-closure glaucoma.

Pilocarpine hydrochloride is indicated for-

  • The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
  • The management of acute angle-closure glaucoma
  • The prevention of postoperative elevated IOP associated with laser surgery
  • The induction of miosis 

Instill one drop in the eye(s) up to four times daily.

Most common adverse reactions are-

  • headache/browache
  • accommodative change
  • eye irritation
  • eye pain
  • blurred vision
  • visual impairment
  • Poor lighting: Use caution when driving at night and performing other hazardous occupations in poor lighting.
  • Pre-existing retinal disease: Although rare cases of retinal detachment have been reported, all patients should have a thorough examination of the retina, including funduscopy, prior to starting therapy.
  • Iritis: Patients with iritis should exercise caution.
  • Congenital glaucoma: Caution is advised for IOP control in pediatric patients with primary congenital glaucoma, as cases of paradoxical increase in IOP have been reported.

Contraindication